Literature DB >> 28239271

Why do we still have Helicobacter Pylori in our Stomachs.

Amin Talebi Bezmin Abadi1, Enzo Ierardi2, Yeong Yeh Lee3.   

Abstract

The existence of any infectious agent in a highly acidic human stomach is contentious, but the chance finding of Helicobacter pylori is by no means an accident. Once H. pylori colonises the gastric mucosa, it can persist for a lifetime, and it is intriguing why our immune system is able to tolerate its existence. Some conditions favour the persistence of H. pylori in the stomach, but other conditions oppose the colonisation of this bacterium. Populations with high and extremely low prevalence of H. pylori provide useful insights on the clinical outcomes that are associated with this type of infection. Adverse clinical outcomes including peptic ulcer disease and gastric cancer depend on a delicate balance between a harmless inflammation and a more severe kind of inflammation. Is the only good H. pylori really a dead H. pylori? The jury is still out.

Entities:  

Keywords:  Helicobacter pylori; elimination; gastric cancer; peptic ulcer disease; stomach; survival

Year:  2015        PMID: 28239271      PMCID: PMC5295741     

Source DB:  PubMed          Journal:  Malays J Med Sci        ISSN: 1394-195X


  22 in total

1.  Lactobacilli for the management of Helicobacter pylori.

Authors:  M Alsahli; P Michetti
Journal:  Nutrition       Date:  2001-03       Impact factor: 4.008

2.  Analysis of surface-exposed outer membrane proteins in Helicobacter pylori.

Authors:  Bradley J Voss; Jennifer A Gaddy; W Hayes McDonald; Timothy L Cover
Journal:  J Bacteriol       Date:  2014-04-25       Impact factor: 3.490

3.  Infection with Helicobacter pylori strains lacking dupA is associated with an increased risk of gastric ulcer and gastric cancer development.

Authors:  Amin Talebi Bezmin Abadi; Tarang Taghvaei; Lutz Wolfram; Johannes G Kusters
Journal:  J Med Microbiol       Date:  2011-09-08       Impact factor: 2.472

4.  Sociocultural and dietary practices among Malay subjects in the north-eastern region of Peninsular Malaysia: a region of low prevalence of Helicobacter pylori infection.

Authors:  Yeong Yeh Lee; Ahmad Wazi Ismail; Nazri Mustaffa; Kamarul Imran Musa; Noorizan Abdul Majid; Keng Ee Choo; S Mahendra Raj; Mohammad H Derakhshan; Hoda M Malaty; David Y Graham
Journal:  Helicobacter       Date:  2012-02       Impact factor: 5.753

Review 5.  The role of interleukin-1beta and other potential genetic markers as indicators of gastric cancer risk.

Authors:  Esther Troost; Georgina L Hold; Malcolm G Smith; Wong-Ho Chow; Charles S Rabkin; Kenneth E L McColl; Emad M El-Omar
Journal:  Can J Gastroenterol       Date:  2003-06       Impact factor: 3.522

6.  Association of Malaysian Helicobacter pylori virulence polymorphisms with severity of gastritis and patients' ethnicity.

Authors:  Hanafiah Alfizah; Mohamed Ramelah; Abdul M Rizal; Abdullah S Anwar; Mohamed R Isa
Journal:  Helicobacter       Date:  2012-04-25       Impact factor: 5.753

Review 7.  Environmental and lifestyle risk factors of gastric cancer.

Authors:  Yeong Yeh Lee; Mohammad H Derakhshan
Journal:  Arch Iran Med       Date:  2013-06       Impact factor: 1.354

8.  High frequency of A2143G mutation in clarithromycin-resistant Helicobacter pylori isolates recovered from dyspeptic patients in Iran.

Authors:  Amin T Abadi; Tarang Taghvaei; Ali Ghasemzadeh; Ashraf M Mobarez
Journal:  Saudi J Gastroenterol       Date:  2011 Nov-Dec       Impact factor: 2.485

9.  Absence of Helicobacter pylori is not protective against peptic ulcer bleeding in elderly on offending agents: lessons from an exceptionally low prevalence population.

Authors:  Yeong Yeh Lee; Nordin Noridah; Syed Abdul Aziz Syed Hassan; Jayaram Menon
Journal:  PeerJ       Date:  2014-02-11       Impact factor: 2.984

Review 10.  Therapy of Helicobacter pylori: present medley and future prospective.

Authors:  Amin Talebi Bezmin Abadi
Journal:  Biomed Res Int       Date:  2014-04-01       Impact factor: 3.411

View more
  8 in total

1.  Resistance to clarithromycin and gastroenterologist's persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization.

Authors:  Amin Talebi Bezmin Abadi
Journal:  World J Gastroenterol       Date:  2017-09-21       Impact factor: 5.742

2.  Phyto anti-biofilm elicitors as potential inhibitors of Helicobacter pylori.

Authors:  Ashwini Prasad; Aishwarya Tripurasundari Devi; M N Nagendra Prasad; Farhan Zameer; Govindaraju Shruthi; Chandan Shivamallu
Journal:  3 Biotech       Date:  2019-01-25       Impact factor: 2.406

3.  Evaluation of Better Staining Method among Hematoxylin and Eosin, Giemsa and Periodic Acid Schiff-Alcian Blue for the Detection of Helicobacter pylori in Gastric Biopsies.

Authors:  Abdullah Saleh Alkhamiss
Journal:  Malays J Med Sci       Date:  2020-10-27

Review 4.  Strategies used by helicobacter pylori to establish persistent infection.

Authors:  Amin Talebi Bezmin Abadi
Journal:  World J Gastroenterol       Date:  2017-04-28       Impact factor: 5.742

5.  Comment on "Gastric and colon metastasis from breast cancer: case report, review of the literature, and possible underlying mechanisms".

Authors:  Amin Talebi Bezmin Abadi
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-02-24

Review 6.  Diagnosis of Helicobacter pylori Using Invasive and Noninvasive Approaches.

Authors:  Amin Talebi Bezmin Abadi
Journal:  J Pathog       Date:  2018-05-22

7.  Helicobacter pylori and gastrointestinal and neurological diseases: Study protocol of an umbrella review of systematic reviews and meta-analyses.

Authors:  Baoning Wang; Jing Zhang; Sihan Chen; Mingjiang Bie
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

8.  From genes polymorphisms to mucosal expression of cytokines: evaluating IL-23/IL-17 axis in adult patients with gastritis.

Authors:  Fatemeh Azadegan-Dehkordi; Ardeshir Abbasi; Amin Talebi Bezmin Abadi; Khaled Minooie; Parya Aslani; Razieh Sadat Hosseini; Farid Zandi
Journal:  Afr Health Sci       Date:  2020-09       Impact factor: 0.927

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.